Amanote Research
Register
Sign In
P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.595
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
M. Huang
Y. Tian
M. He
L. Ren
Y. Gong
F. Peng
Y. Wang
Z. Ding
J. Wang
J. Zhu
Y. Xu
Y. Liu
L. Li
Y. Lu
Publisher
Elsevier BV